Axsome Therapeutics (NASDAQ:AXSM) Given New $195.00 Price Target at Mizuho

Axsome Therapeutics (NASDAQ:AXSM) had its target price boosted by equities research analysts at Mizuho from $137.00 to $195.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Mizuho’s target price would suggest a potential upside of 53.45% from the stock’s previous close.

A number of other analysts have also recently weighed in on AXSM. William Blair reaffirmed an “outperform” rating on shares of Axsome Therapeutics in a research note on Friday, January 24th. Leerink Partners upped their target price on Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a report on Monday. Royal Bank of Canada reissued an “outperform” rating and set a $139.00 price target on shares of Axsome Therapeutics in a research note on Wednesday, January 29th. Robert W. Baird raised their price objective on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Finally, HC Wainwright boosted their target price on shares of Axsome Therapeutics from $180.00 to $190.00 and gave the stock a “buy” rating in a report on Friday, January 31st. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $141.73.

Axsome Therapeutics Stock Performance

NASDAQ:AXSM opened at $127.08 on Tuesday. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. The firm has a market capitalization of $6.16 billion, a PE ratio of -19.46 and a beta of 1.05. Axsome Therapeutics has a twelve month low of $64.11 and a twelve month high of $132.25. The stock’s 50-day simple moving average is $94.72 and its 200 day simple moving average is $91.78.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.38) by $0.04. The company had revenue of $104.76 million for the quarter, compared to analyst estimates of $98.71 million. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same period in the previous year, the firm posted ($1.32) EPS. On average, analysts anticipate that Axsome Therapeutics will post -4.7 EPS for the current fiscal year.

Institutional Trading of Axsome Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Assetmark Inc. bought a new stake in Axsome Therapeutics in the fourth quarter valued at $52,000. R Squared Ltd acquired a new position in Axsome Therapeutics during the 4th quarter worth approximately $64,000. KBC Group NV grew its stake in Axsome Therapeutics by 40.5% in the fourth quarter. KBC Group NV now owns 1,336 shares of the company’s stock valued at $113,000 after acquiring an additional 385 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Axsome Therapeutics by 22.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after acquiring an additional 318 shares in the last quarter. Finally, Moors & Cabot Inc. acquired a new position in shares of Axsome Therapeutics during the third quarter worth approximately $200,000. Institutional investors own 81.49% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.